依據歐盟施行的個人資料保護法，我們致力於保護您的個人資料並提供您對個人資料的掌握。
按一下「全部接受」，代表您允許我們置放 Cookie 來提升您在本網站上的使用體驗、協助我們分析網站效能和使用狀況，以及讓我們投放相關聯的行銷內容。您可以在下方管理 Cookie 設定。 按一下「確認」即代表您同意採用目前的設定。
Recycle Insight
2026: The Dawn of Regenerative Medicine — Accelerating Cell Therapy and the Rise of iPSC Technology
In 2026, Taiwan’s “Dual Regenerative Medicine Acts” officially came into force, marking a new stage in the development of the regenerative medicine industry. As advancements in cell therapy, gene technology, and biomaterials research continue to accelerate, the global medical and biotechnology sectors are actively exploring the diverse potential applications of regenerative medicine.
Through collaboration with Japan on iPSC technology and related patent licensing, MetaTech Biomed has invested in cell-related research and is exploring a variety of iPSC-derived applications. These include research directions that have gained increasing attention in recent years, such as “i-ReMeta (iPSC-derived exosomes).”